Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
Manso Sánchez, Luis
creator
Oncología Médica
Servicio de Oncología Médica
text
xxx
Annals of oncology: official journal of the European Society for Medical Oncology
2013
eng
24(1):109-16.
BACKGROUND: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer.
Formato Vancouver:
Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013
Jan;24(1):109-16.
PMID: 22967996
Contiene 43 referencias
http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1560.pdf
http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1560.pdf
130622
20180417112018.0